Are Patients with Coronavirus Disease 2019 and Obesity at a Higher Risk of Hospital and Intensive Care Unit Admissions? A Systematic Review and Meta-analysis

Anggi Lukman Wicaksana1,2,6, Nuzul Sri Hertanti3,4, Raden Bowo Pramono4,5, Yu-Yun Hsu6

1Department of Medical Surgical Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; 2The Sleman Health and Demographic Surveillance System, Universitas Gadjah Madya, Yogyakarta, Indonesia; 3Center for Tropical Medicine, Universitas Gadjah Madya, Yogyakarta, Indonesia; 4Department of Internal Medicine, Universitas Gadjah Madya, Yogyakarta, Indonesia; 5Department of Internal Medicine, Dr. Sardjito General Hospital, Yogyakarta, Indonesia; 6Department of Nursing, National Cheng Kung University, Tainan, Taiwan, Republic of China

Abstract

BACKGROUND: Obesity, common condition among patients with coronavirus disease 2019 (COVID-19), contributes to illness severity during hospitalization. To date, knowledge on the prevalence, risk of hospital and intensive care units (ICU) admissions and mortality is limited. Therefore, systematic review and meta-analysis were conducted using a preferred reporting items for systematic reviews and meta-analyses guideline.

AIM: The study aimed to address the prevalence, risk of hospital and ICU admissions and mortality among patients with COVID-19 and obesity.

METHODS: The Newcastle–Ottawa scale was used to assess the quality of a study. Primary outcomes were the prevalence and risk of hospitalization, and secondary outcomes were the risk of ICU admissions and mortality risk. Mantel–Haenszel with random effects was applied, and the effect measure was odds ratio (OR) with 95% confidence interval (CI).

RESULTS: Nine studies were included in the systematic review, and only four studies for meta-analysis. Among 29,776 patients with COVID-19, obesity was identified as the second-highest comorbidity. The prevalence rates of obesity and severe obesity among patients with COVID-19 were 26.1% and 15.5%, respectively. Obesity resulted in significantly increased risk of hospital admission (OR = 1.77, 95% CI = 1.52–2.06, p < 0.00001) and ICU admission (OR = 1.79, 95% CI = 1.42–2.25, p < 0.00001). The mortality rate of patients with COVID-19 and obesity was about 30.5% (438/1,434), and 19.7% (2,777/14,095) of them recovered from COVID-19.

CONCLUSION: Obesity poses as nearly twice the risk of hospital and ICU admissions, and severe obesity contributes to almost twice the risk of ICU admissions.

Introduction

Chronic diseases, such as hypertension, diabetes, heart, and pulmonary diseases, have been recognized and associated with the severity of coronavirus disease 2019 (COVID-19) [1, 2, 3]. Among all chronic conditions, obesity has been seldom identified as a risk factor of COVID-19 [3], [4], [5], [6]. The previous studies identified that obesity or the body mass index (BMI) is equal to or more than 30, was major risk factor for the severity of COVID-19 [1], [7], [8]. The prevalence rate of obesity among patients with COVID-19 varies. Bello-Chavolla et al. [1] reported 20.7% patients with COVID-19 and obesity, whereas Richardson et al. [9] reported 41.7% patients with COVID-19 and obesity. Other studies have also reported a different prevalence rate of obesity from 26.8% to 47.5% among patients COVID-19 [2], [10], [11]. To date, COVID-19 is spreading worldwide, especially in areas where obesity is mostly dominant, such as North American and European countries [3].

Obesity in patients with COVID-19 is associated with adverse outcomes [1, 12, 13] and affects patients’ outcomes [2], [3], [7], [10], [11]. Patients with severe COVID-19 and obesity require more hospitalization [10], and some of them even need intensive care because of the nature of disease progression [3], [5], [7], [10], [12]. Furthermore, obesity contributes to the occupation of invasive mechanical ventilation [2], [3] and increases the risk of mortality of patients with COVID-19 [1], [13].

The effect of obesity on patients with COVID-19 should be explored [3]. Health-care providers and policy makers must identify the risk level and outcomes related to COVID-19 [11]. However, the previous studies were limited in terms of particular areas/countries and number of participants, resulting in...
a wide range of outcomes of the risk level and causing difficulty in decision-making.

A systematic review and meta-analysis to identify the prevalence of obesity, the risk of hospital and intensive care unit (ICU) admissions, and the mortality risk among patients with COVID-19 and obesity and severe obesity, was conducted. The study aimed to address the following questions: (a) Are patients with COVID-19, obesity, and severe obesity at a high risk of hospital admissions? (b) Are patients with COVID-19, obesity, and severe obesity at a high risk of ICU admissions? (c) Are patients with COVID-19, obesity, and severe obesity at a high risk of mortality?

Methods

The systematic review and meta-analysis study were conducted and the guideline of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) protocol [14] was applied for selecting the articles.

Eligibility criteria

The prevalence and risk of hospital admissions were determined as the primary outcomes, and the risk of ICU admission and mortality risk was identified as the secondary outcomes. The study design was limited to prospective and retrospective cohort or case control studies. Only published articles in 2020 and written in English were included in the study. The preprint articles did not included to minimize the bias and only peer-reviewed articles were involved. The targeted populations were classified as (1) all patients with COVID-19 and obesity (BMI ≥30) and (2) those who had COVID-19 and severe obesity (BMI ≥35). Commentaries, abstracts, news, editorials, and case reports were excluded from the study.

Search strategy

Science Direct, PubMed, Clinical Keys, and Google Scholar databases were used with two authors (N.S.H. and A.L.W.) were independently searched. Any different findings were communicated and consulted to the third author (R.B.P.). The medical subject heading (MeSH) terms (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2”) AND “Obesity” AND “Hospital Admission” were used in all the databases from January 1, 2020, to May 10, 2020. Researchers searched and used MeSH terms in PubMed as standard terms, and then the terms were used in other databases to make sure the systematic search. The MeSH terms represent biomedical concepts in particular context as assigned label. Articles were selected using the Microsoft Excel spreadsheet and extracted by two authors (N.S.H. and A.L.W.). All the studies that fitted the inclusion criteria were included in the systematic review. From each study, following data were extracted as the number of patients COVID-19; median age; number of males; prevalence of obesity, diabetes, and hypertension; number of hospitalized patients with COVID-19; number of patients who suffered from COVID-19 and were admitted to the ICU; and number of survivors or nonsurvivors. Obesity (BMI ≥ 30) and severe obesity (BMI ≥ 35) were identified when data were available for comparison.

Risk of bias assessment

Newcastle–Ottawa quality assessment scale (NOS) was used to assess the quality of nonrandomized studies in meta-analysis. The NOS was available for case control and cohort studies [15]. For this review, scoring outcomes were classified into three categories, that is, low (<5 stars), moderate (5–7 stars), and high quality (more than 7 stars) [16]. Only studies with at least five stars (moderate level) were analyzed. Funnel plots and Egger’s regression test was utilized to assess publication bias. The publication bias was identified when the studies were asymmetrically distributed or when their concentration at the bottom of the funnel plots was high [17]. Egger’s regression test was performed to detect the asymmetry of the funnel plots. The absence of a significant outcome indicated there is no bias on the selected studies [18].

Data synthesis and analysis

Data were examined using Review Manager 5.3 [19] and comprehensive meta-analysis (CMA) version 3.0 (trial) [20]. The extracted data were classified into primary and secondary outcomes. They were assembled using the random effects of the Mantel–Haenszel model with OR as the effect measure with 95% CI. The Higgins I² statistic was utilized to check the heterogeneity among groups [21]. The heterogeneity outcomes were classified into low, moderate, and high when the I² was less than 25%, 25–75%, and more than 75%, respectively [16], [22]. Meta-regression with random effect was carried out to explore heterogeneity if the dataset was unavailable to run a sub-group analysis [23].

Results

Outcomes of characteristics of the included studies

Open Access Maced J Med Sci. 2021 Oct 20; 9(F):410-419. 411
At the initial steps, 246 studies were found in the four databases. After duplications were removed, 231 papers were retained for reviewing their abstracts and titles. Only nine studies met the eligibility criteria and were included for a full-text review. They also fitted the criteria for systematic review and provided primary (nine studies on the prevalence of obesity and three studies on the risk of hospital admissions) and secondary outcomes (four studies on the risk of ICU admissions and one study on the risk of mortality; (Table 1). Among the nine studies, only four [1], [2] [10], [11] were eligible for meta-analysis (Figure 1). After the quality was assessed, six and three studies were found to have high and moderate qualities (5–9 stars), respectively. All of the four studies that were included in the meta-analysis indicated a high quality of assessment (8–9 stars).

![The PRISMA flow chart of the included studies](https://oamjms.eu/index.php/mjms/index)

Figure 1: The PRISMA flow chart of the included studies

The total number of patients who had COVID-19 was reported from the nine included studies was 29,776. The median age was between 52 and 72 years, and males were predominant. Obesity was identified as the second-highest comorbidity among patients with COVID-19 (Table 2). All the studies were from American and European countries. Among the nine studies, two studies did not provide the complete information on obesity among patients with COVID-19 but without obesity (Table 2).

### Prevalence of obesity

The prevalence of obesity among patients with COVID-19 was reported between 20.2% and 47.6% from the nine studies (Table 2). The five studies provided information on the prevalence of severe obesity among patients with COVID-19 from 13.9% to 28.2% (Table 3).

The information about the number of patients with obesity and severe obesity among patients with COVID-19 is presented in Table 3. The pooled prevalence of obesity among patients with COVID-19 from the nine studies was 26.1% (7,759/29,776). By comparison, the pooled prevalence of severe obesity among the patients with COVID-19 from the five included studies was 15.5% (1,516/9,799).

### Risk of hospital admissions

The rates of hospital admissions among patients with COVID-19 were between 36.8% and 100%. Five [2], [3], [9], [24], [25] out of the nine studies showed a hospital admission of 100% among the patients with COVID-19 because their study participants were mainly hospitalized patients with COVID-19. The total number of the hospitalized patients with COVID-19 was 17,997 from all the nine studies (Table 2).

Only three [1], [10], [11] out of the nine studies provided the information on obesity among the hospitalized patients with COVID-19. Among 9,372 hospitalized patients with COVID-19, 2896 (30.9%) had obesity. Obesity was the second-highest comorbidity following hypertension. Obesity in patients with COVID-19 resulted in a significantly increased risk of hospital admission with OR = 1.99 (95% CI = 1.12–3.53, \( p = 0.02, \tau^2 = 0.25, I^2 = 99\%\)), compared with patients with COVID-19 but without obesity (Figure 2).

Only one study [10] provided data about severe obesity among the patients with COVID-19. A total of 233 (17.5%) and 362 (15.8%) patients with COVID-19 and severe obesity were hospitalized and nonhospitalized, respectively.

### Table 1: Studies providing data related to outcomes (n = 9)

| Study | Obesity prevalence | ICU admission | Mortality risk |
|-------|--------------------|---------------|---------------|
| BMI ≥ 30 | BMI ≥ 35 | BMI ≥ 30 | BMI ≥ 35 | BMI ≥ 30 | BMI ≥ 35 |
| Belli-Chavola et al. [1] | X | X | | | |
| Cummings, et al. [24] | X | X | | | |
| Petrelli, et al. [11] | X | X | | | |
| McMichael, et al. [25] | X | X | | | |
| Garg, et al. [25] | X | X | | | |
| Simonnet, et al. [3] | X | X | | | |
| Lichter, et al. [10] | X | X | X | X | X |
| Richardson, et al. [9] | X | X | | | |
| Kalligeros, et al. [2] | X | X | | | |

A: Data were available. BMI: Body mass index. ICU: Intensive care unit.
Risk of ICU admissions

Of the nine studies, seven [1, 2, 3, 9, 10, 11, 24] reported the data about ICU admissions, with a total of 3,463 patients with COVID-19. Approximately 4.4–100% patients had COVID-19 and were admitted to the ICU. Simonnet et al. [3] showed that only 100% of the patients with COVID-19 were admitted to ICU, because all of the study participants were recruited from the ICU (Table 2).

Table 2: Number of patients who had COVID-19 with obesity (BMI ≥ 30).

| Study | BMI ≥ 30 (obesity) | BMI ≥ 35 (severe obesity) |
|-------|---------------------|---------------------------|
| Total | n (%)               | Total patients            |
| Bello-Chavola et al. [1] | 3,215 (20.7) | 15,529 | 15,529 |
| Cummings, et al. [24] | 257 | 119 (46.3) | 257 |
| Petriti, et al. [11] | 1,100 (26.8) | 4,103 | 4,103 |
| McMichael, et al. [38] | 37 (22.2) | 173 (41.1) | 173 |
| Garg, et al. [25] | 73 (41.1) | 35 (28.2) | 35 |
| Simonnet, et al. [3] | 59 (47.6) | 1,370 (37.9) | 1,370 |
| Lighter, et al. [10] | 1,370 (37.9) | 60 (16.5) | 60 |
| Richardson, et al. [9] | 1,737 (41.7) | 60 (16.5) | 60 |
| Kagleros, et al. [2] | 49 (47.5) | 1,999 (48.7) | 1,999 |
| Total | 5,700 | 14,864 | 14,864 |

The information on patients who had COVID-19 and severe obesity and were admitted to the ICU was only available from two studies [2, 10] for meta-analysis. Of 475 patients with COVID-19 who were admitted to the ICU, 120 had severe obesity (25.3%). In comparison with patients with COVID-19 but without severe obesity, those with severe obesity had a significantly increased risk of ICU admission (OR 1.79, 95% CI 1.42-2.25, p < 0.00001, Tau² = 0.00, I² = 0%, Figure 4).

Mortality risk

Only one study [1] provided information about the mortality rate of patients with COVID-19 and obesity but did not have data on severe obesity. Of 14,095 COVID-19 survivors, 2,777 (19.7%) had obesity. However, of the 1,434 patients who died of COVID-19, 438 (30.5%) had obesity.

Meta-regression outcomes

Meta-regression was applied to explore the high heterogeneity in meta-analysis outcomes. I² of the risk of hospital admissions among patients with COVID-19 and obesity patients indicated a high heterogeneity. The CMA, however, could not be utilized for the analysis because of limited number of studies included in meta-regression.

The meta-regression of heterogeneity was conducted to explore the heterogeneity by using the design (retrospective vs. prospective) and location (USA vs. Mexico) as covariates. However, meta-regression was only performed for the design covariate, and it was not doable for location covariate because of the limited numbers of studies (n = 2). The outcomes of meta-regression showed β = -0.235...
and standard error = 0.110 (Q = 4.53, df = 1, 95% CI = –0.452 to –0.018, p = 0.034); the goodness-of-fit outcomes were \( \tau^2 = 0.010, \tau = 0.1007, I^2 = 44.9\% \), and \( R^2 \) analog = 1 (Q = 5.45, df = 3, p = 0.142). These results indicated that the covariate of the retrospective design significantly contributed to a decrease of 0.235 units in the risk of ICU admissions among patients with COVID-19 and obesity.

**Bias assessment**

The funnel plots indicated a symmetrical shape and a non-higher concentration at the bottom of the funnel plots (Additional file: Figure S1-3). Furthermore, Egger’s regression yielded intercept = 9.845, 95% CI = –248.312 to 268.001, df = 1, p = 0.713 for hospital admission and intercept = –0.067, 95% CI = –0.927 to –0.907, df = 2, p = 0.977 for ICU admissions among patients with obesity. These findings showed that the funnel plot had no asymmetry. The analysis on the publication bias of the risk of ICU admissions among patients with severe obesity was inapplicable because a minimum of three studies was not achieved.

**Discussion**

This study addressed the prevalence, risk of hospital and ICU admissions, and risk of mortality among patients with COVID-19, obesity, and severe obesity using available published data. To our best knowledge, this study was the first to extensively perform a systematic review and meta-analysis and address the aforementioned questions, particularly for severe obesity. Our findings revealed that 26.1% and 15.5% of patients with COVID-19 had obesity and severe obesity, respectively. The risk of hospital and ICU admissions of the patients with COVID-19 and obesity was twice higher that of the patients without obesity. Furthermore, COVID-19 patients with severe obesity had almost twice risks of ICU admission than non-severe obese COVID-19 patients.

The previous studies had limitations on the regional report and some reported small cases of COVID-19. The current study presented a pooled data of obesity and severe obesity on COVID-19 patients. The previous study showed a pooled prevalence of obesity was about 33.9%, relatively higher than these findings [26]. Furthermore, obesity was identified as the second-highest prevalence of comorbidity among COVID-19, particularly in American and European countries. This finding was different from previous results that highlighted diabetes as the second-largest comorbidity among patients with COVID-19 [16], [27], [28], [29]. The previous studies rarely assessed obesity among patients with COVID-19. Thus, this finding might reflect the basic characteristics of the population [16], especially in areas with a high prevalence of obesity.

Obesity and severe obesity in patients with COVID-19 were associated with poor outcomes, namely, hospital admission, ICU admission, and mortality. The current meta-analyses indicated that patients with COVID-19 and obesity had almost twice
the risk of hospital admissions. These results were in accordance with other meta-analysis, in which identified the OR about 1.3–2.3 [30], [31], [32]. Obesity and severe obesity significantly increased the risk of ICU admissions among patients with COVID-19 with moderate heterogeneity, by 77% and 79%, respectively. The outcome of twice risks of ICU admissions among patients with COVID-19 and obesity was similar with the previous meta-analysis (OR 1.3–2.3) [30], [31], [32]. BMI ≥30 and a history of heart diseases are independently associated with the use of invasive mechanical ventilation [2], [31], [32]. The mechanism of obesity contributing to the severity level of COVID-19 is recommended [2]. Obesity caused multistranded pathophysiology, such as hyperactivation, increased interleukin-6 (IL-6) concentration, inflammation, and presence of other comorbidities [33]. Abdominal obesity leads to impaired lung ventilation and reduced oxygen saturation [7], [34]. A study on pulmonary function has shown that patients with obesity have restrictive and decreased lung volumes [35]. Some studies have indicated that patients with COVID-19 and severe obesity are subjected to long-term invasive mechanical ventilation [3], [7].

Obesity is associated with increased IL-6 [7], [33] and C-reactive protein contents [7]. Any abnormal secretion of interferon, adipokines, and cytokines (i.e. tumor necrotic factor alpha) result in a chronic low-grade inflammation. This condition potentially impairs the immune system by dysregulating the expression of tissue leukocyte [3], [7], [36]. Obesity and metabolic syndrome increase type 2 inflammation that impacts the lung parenchyma and bronchi [37], [38]. Obesity can stimulate insulin resistance and decrease beta-cell function. Consequently, insulin must be administered during a severe infection, thereby impairing host defense and leading to immunological deficit. In addition, obesity exacerbates the thrombosis that corresponds to prothrombotic disseminated intravascular coagulopathy and venous thromboembolism in patients with COVID-19 [7].

The heterogeneity outcome of the risk of hospital admissions of patients with COVID-19 and obesity was high. Furthermore, meta-regression could not be performed to explore heterogeneity because of the limited number of studies included for analysis [20]. We acknowledged that the unexplained heterogeneity of these results might affect the inconsistency across the studies [22], [23]. Thus, further studies on hospital admissions among patients with COVID-19 and obesity should be performed to investigate such inconsistencies. Only Lighter et al. [10] reported the data about the risk of hospitalization among patients with COVID-19 and severe obese, with OR = 2.2 (95% CI = 1.7–2.9, p < 0.0001). Another study has identified that BMI >40 contributes to 6.2 times (95% CI = 4.2–9.3) of the hospitalization risk [11]. The retrospective design covariate significantly helped decrease the risk of ICU admissions among the patients with COVID-19 and obesity by 0.235 units. The covariate of the retrospective design resulted in R² analog = 1, which indicated that the covariate of the retrospective design could explain all variances [20].

**Strength and limitation of the study**

This systematic review and meta-analysis had several limitations related to the nature of the study. The studies for meta-analysis were limited, although the nine included studies considered of a large number of patients with obesity or severe obesity as participants. The risk of hospital and ICU admissions among patients with COVID-19 and obesity might be underestimated because the accessibilities of hospital beds or ICU units are restricted. The high heterogeneity on the risk of hospital admission among patients with COVID-19 and obesity is also unexplained. Subgroup analysis is not workable because of the limited data and numbers of included studies. Furthermore, this study did not identify the risk of hospital admissions among patients with COVID-19 severe obesity because of limited data. Few studies have provided data about the survivorship of patients with COVID-19 and obesity or severe obesity. Thus, future research related to the survivorship of these patients should be conducted.

**Conclusion**

This systematic review identified that the prevalence rates of obesity and severe obesity were 26% and 15% among patients with COVID-19, respectively. Patients with COVID-19 and obesity had twice the risks of hospital and ICU admissions compared with those of patients with COVID-19 but without obesity. Remarkably, patients with COVID-19 and severe obesity also showed approximately twice the risks for ICU admission compared with those of patients with COVID-19. Populations and health-care providers should notice and be aware of the high risk of hospital and ICU admissions among patients with COVID-19, obesity, and severe obesity.

This review provides valuable information on the high risk of hospital and ICU admissions for patients with COVID-19, obesity, and severe obesity. Health-care providers should intensively monitor the health outcomes these groups of patient. In addition, patients with obesity or severe obesity and their families should be aware of their risks of the severity of COVID-19 and minimize contact with other patients with COVID-19. Health-care providers should also provide valid education on COVID-19 prevention and raise the awareness related to a high risk among patients with COVID-19 and obesity or severe obesity.
Additional file 1: Supplementary methods, PRISMA checklist. Figure S1, Funnel plots of the included studies on the risk of hospital admissions among patients with COVID-19 and obesity. Figure S2, Funnel plots of the included studies on the risk of ICU admissions among patients with COVID-19 and obesity. Figure S3, Funnel plots of the included studies on the risk of ICU admissions among patients with COVID-19 and severe obesity.

References

1. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas- Vázquez A, González-Díaz A, Márquez-Salinas A, et al. Predicting mortality due to SARS-CoV-2: A mechanistic approach. J Clin Endocrinol Metab. 2020;105(8):dga436. https://doi.org/10.1002/1440-3485.14004
PMid:32475498

2. Kalligeros M, Shehadeh F, Mlynka EK, Benitez G, Beckwith CG, Chan PA, Mylonakis E. Association of obesity with disease severity among patients with Coronavirus disease 2019. Obesity (Silver Spring). 2020;28(7):1200-4. https://doi.org/10.1002/oby.22859
PMid:32526337

3. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020;29(7):1195-9. https://doi.org/10.1002/oby.22831
PMid:32271993

4. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-207. https://doi.org/10.1056/nejmoa2004500
PMid:31995587

5. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574-81. https://doi.org/10.1001/jama.2020.5640
PMid:32250385

6. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger AL, Pipavath S, Wurfel MM, Evans L, Kritek PA. COVID-19 in critically ill patients in the Seattle region: A case series. N Engl J Med. 2020;382(21):2012-22. https://doi.org/10.1056/nejmoa2004500
PMid:32227758

7. Sattar N, McInnes IB, McMurray JJ. Obesity is a risk factor for severe COVID-19 infection: Multiple potential mechanisms. Circulation. 2020;142(1):4-6. https://doi.org/10.1161/circulationaha.120.047659
PMid:32320270

8. Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang TY, et al. Letter to the editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. https://doi.org/10.1016/j.metabol.2020.154244
PMid:32320741

9. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9. https://doi.org/10.1001/jama.2020.6775
PMid:32320003

10. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71(15):896-7. https://doi.org/10.1093/cid/ciaa415
PMid:32271368

11. Petrelli CM, Jones SA, Yang J. Factors associated with hospital admission and critical illness among 5279 patients with Coronavirus disease 2019 in New York city prospective cohort study. BMJ. 2020;369;m1966. https://doi.org/10.1136/bmj.m1966
PMid:32444366

12. Jose RJ, Manuel A. Does Coronavirus disease 2019 disprove the obesity paradox in acute respiratory distress syndrome? Obesity (Silver Spring). 2020;28(6):1007. https://doi.org/10.1002/oby.22835
PMid:32294322

13. Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring). 2020;28(6):1005. https://doi.org/10.1002/oby.22835

14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8(5):336-41. https://doi.org/10.1016/j.jsu.2010.02.007
PMid:20171303

15. Wells GA, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality if Nonrandomized Studies in Meta-Analyses. Ottawa Hospital Research Institute. Clinical Epidemiology; 2016. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. [Last accessed on 2020 Aug 13].

16. Roncon L, Zuin M, Rigattelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol. 2020;127:104354. https://doi.org/10.1016/j.jcv.2020.104354
PMid:32305882

17. Borenstein M. Software for publication bias. In: Rothstein HR, Sutton AJ, Borenstein M, editors. Publication Bias in Meta-Analyses: Prevention, Assessment and Adjustments. England: John Wiley and Sons; 2005. https://doi.org/10.1002/0470870168

18. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(709):629-34. https://doi.org/10.1136/bmj.315.7109.629
PMid:9310563

19. Collaboration C, Review Manager (RevMan) [computer program] Version 5.2. 3, The Nordic Cochrane Centre, Copenhagen, 2012. Health Psychol Rev. 2014;17.

20. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Comprehensive Meta-Analysis. 2nd ed. United Kindom: Biostat; 2009.

21. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I² index? Psychol Methods. 2006;11(2):193-206. https://doi.org/10.1037/1082-989x.11.2.193

22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
Wicaksana et al. Patients with Coronavirus Disease 2019 and Obesity at Higher Risk

23. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559-73. https://doi.org/10.1002/sim.1187 PMid:12111920

24. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balou EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study. Lancet. 2020;395(10239):1763-70. https://doi.org/10.1016/s0140-6736(20)31189-2 PMid:32442528

25. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus disease 2019-COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):456-64. https://doi.org/10.15585/mmwr.mm6915e3 PMid:3298251

26. Malik P, Patel U, Patel K, Martin M, Shah C, Mehta D, Malik FA, Sharma A. Obesity a predictor of outcomes of COVID-19 hospitalized patients—a systematic review and meta-analysis. J Med Virol. 2021;93(2):1188-93. https://doi.org/10.1002/jmv.26555 PMid:32975814

27. Hill MA, Mantzoros C, Sowers JR. Commentary: COVID-19 in patients with diabetes. Metabolism. 2020;107:154217. https://doi.org/10.1016/j.metabol.2020.154217 PMid:32220611

28. Wicaksana AL, Hertanti NS, Ferdiana A, Pramono RB. Diabetes management and specific considerations for patients with diabetes during coronavirus diseases pandemic: A scoping review. Diabetes Metab Syndr. 2020;14(5):1109-20. https://doi.org/10.1016/j.dsx.2020.06.070 PMid:32659694

29. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. J Community Empowerment Health. 2020;3(2):77-84. https://doi.org/10.22146/jcoemph.57325

30. Huang Y, Lu Y, Huang YM, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: A systematic review and meta-analysis. Metabolism. 2020;28:154378. https://doi.org/10.1016/j.metabol.2020.154378 PMid:33002478

31. Helvacı N, Eyüpoglu ND, Karabulut E, Yıldız BO. Prevalence of obesity and its impact on outcome in patients with COVID-19: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:598249. https://doi.org/10.3389/fendo.2021.598249 PMid:33716962

32. Zhang X, Lewis AM, Moley JR, Brestoff JR. A systematic review and meta-analysis of obesity and COVID-19 outcomes. Sci Rep. 2021;11(1):7193. https://doi.org/10.1038/s41598-021-86694-1 PMid:33758330

33. Watanabe M, Risi R, Tuccinardi D, Baquero CJ, Manfrini S, Gnassi L. Obesity and SARS-CoV-2: A population to safeguard. Diabetes Metab Res Rev. 2020;36(7):e3325. https://doi.org/10.1002/dmrr.3325 PMid:32314503

34. Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018;12(9):755-67. PMid:30056777

35. Watson RA, Pride NB, Thomas EL, Fitzpatrick J, Durighel G, McCarthy J, et al. Reduction of total lung capacity in obese men: Comparison of total intrathoracic and gas volumes. J Appl Physiol. 2010;108(6):1605-12. https://doi.org/10.1152/japplphysiol.01267.2009 PMid:20299612

36. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes (Lond). 2013;37(3):333-40. PMid:22546772

37. Zhang X, Zheng J, Zhang L, Liu Y, Chen GP, Wang L, et al. Systemic inflammation mediates the detrimental effects of obesity on asthma control. Allergy Asthma Proc. 2018;39(1):43-50. https://doi.org/10.2500/aap.2018.39.4096 PMid:29279059

38. McMichael TM, Currie DW, Clark S, Pogosians S, Kay M, Schwartz NG, et al. Epidemiology of COVID-19 in a long-term care facility in King County, Washington. N Engl J Med. 2020;382(21):2005-11. PMid:32220208
Supplementary

Table of Contents

Supplementary Methods: PRISMA checklist

| Section/topic | # Checklist item | Reported on page # |
|---------------|------------------|-------------------|
| Title         | 1 Identify the report as a systematic review, meta-analysis, or both. | 1 |
| Structured summary | 2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1 |
| ABSTRACT      |                  |                   |
| INTRODUCTION  |                  |                   |
| Rationale     | 3 Describe the rationale for the review in the context of what is already known. | 2 |
| Objectives    | 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 3 |
| METHODS       |                  |                   |
| Protocol and registration | 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | N/A |
| Eligibility criteria | 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 3 |
| Information sources | 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 4 |
| Search        | 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 4 |
| Study selection | 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 3-4 |
| Data collection process | 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 4 |
| Data items    | 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 3-4 |
| Risk of bias in individual studies | 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 4 |
| Summary measures | 13 State the principal summary measures (e.g., risk ratio, difference in means). | 5 |
| Synthesis of results | 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis. | 5 |
| Risk of bias across studies | 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 5 |
| Additional analyses | 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 5 |
| RESULTS       |                  |                   |
| Study selection | 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 5-6,20 |
| Study characteristics | 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 5-6,18 |
| Risk of bias within studies | 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 9 |
| Results of individual studies | 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 6-8 |
| Synthesis of results | 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 6-8, 21-23 |
| Risk of bias across studies | 22 Present results of any assessment of risk of bias across studies (see Item 15). | 9 |
| Additional analyses | 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 8-9 |
| DISCUSSION    |                  |                   |
| Summary of evidence | 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 9-11 |
| Limitations   | 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 11-12 |
| Conclusions   | 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 12 |
| Funding       | 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | Title page #2 |

Figure S1: Funnel plots of the included studies on the risk of hospital admissions among patients with COVID-19 and obesity
Figure S2: Funnel plots of the included studies on the risk of ICU admissions among patients with COVID-19 and obesity
Figure S3: Funnel plots of the included studies on the risk of ICU admissions among patients with COVID-19 and severe obesity
Wicaksana et al. Patients with Coronavirus Disease 2019 and Obesity at Higher Risk

Figure S1: Funnel plots of the included studies on the risk of hospital admissions among patients with COVID-19 and obesity

Figure S2: Funnel plots of the included studies on the risk of ICU admissions among patients with COVID-19 and obesity

Figure S3: Funnel plots of the included studies on the risk of ICU admissions among patients with COVID-19 and severe obesity